Alector, Inc. Contracts & Agreements
44 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (5)
- Human Resources (13)
- Real Estate (2)
- Uncategorized (14)
- Description of securities of the Registrant (Filed With SEC on February 27, 2024)
- 2019 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on February 27, 2024)
- 2019 Employee Stock Purchase Plan and form of agreement thereunder (Filed With SEC on February 27, 2024)
- Outside Director Compensation Policy (Filed With SEC on February 27, 2024)
- Underwriting Agreement, dated January 17, 2024, by and between Alector, Inc. and Cantor Fitzgerald & Co (Filed With SEC on January 19, 2024)
- Sales Agreement, dated November 7, 2023, by and between Alector, Inc., and Cowen and Company, LLC (Filed With SEC on November 7, 2023)
- Letter Agreement Amending the 2021 Collaboration and License Agreement between the Registrant and Glaxo Wellcome UK Ltd. dated May 19, 2023 (Filed With SEC on August 3, 2023)
- 2022 Inducement Equity Incentive Plan, as amended, and related forms of stock option and restricted stock unit agreements (Filed With SEC on September 26, 2022)
- Offer Letter between Alector, Inc. and Gary Romano, Ph.D., M.D (Filed With SEC on March 29, 2022)
- Offer Letter dated November 30, 2021 by and between Alector, Inc. and Saraswati (Sara) Kenkare-Mitra, Ph.D (Filed With SEC on February 24, 2022)
- Offer Letter dated February 7, 2022 by and between Alector, LLC and Marc Grasso, MD (Filed With SEC on February 24, 2022)
- Offer Letter dated February 4, 2022 by and between Alector, Inc.and Marc Grasso, MD (Filed With SEC on February 7, 2022)
- 2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements (Filed With SEC on January 3, 2022)
- Separation Agreement and Release of Claims, dated December 31, 2021, by and between Shehnaaz Suliman and Alector, LLC (Filed With SEC on January 3, 2022)
- Confidential Consulting Agreement, effective September 3, 2021, by and between FLG Partners and Alector, LLC (Filed With SEC on November 4, 2021)
- Transition Agreement, dated September 7, 2021, by and between Shehnaaz Suliman and Alector, LLC (Filed With SEC on September 7, 2021)
- Letter Agreement, dated September 7, 2021, by and between Robert Paul and Alector, LLC (Filed With SEC on September 7, 2021)
- Retention Letter Agreement, dated March 23, 2021, among Mr. Calvin Yu and Alector, Inc (Filed With SEC on March 26, 2021)
- Description of securities of the Registrant (Filed With SEC on February 25, 2021)
- Equity Distribution Agreement, dated May 13, 2020, by and among Alector, Inc., Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC (Filed With SEC on May 13, 2020)
- Description of securities of the Registrant (Filed With SEC on March 24, 2020)
- Outside Director Compensation Policy (Filed With SEC on March 24, 2020)
- Underwriting Agreement, dated as of January 29, 2020, among the Registrant, Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC,... (Filed With SEC on February 4, 2020)
- Form of Underwriting Agreement, including Form of Lock-up Agreement (Filed With SEC on January 27, 2020)
- 2019 Collaboration Agreement between the Registrant and Adimab, LLC, dated August 16, 2019 (Filed With SEC on November 12, 2019)
- Confirmatory Offer Letter between the Registrant and Arnon Rosenthal, Ph.D (Filed With SEC on January 29, 2019)
- Confirmatory Offer Letter between the Registrant and Robert Paul, M.D., Ph.D (Filed With SEC on January 29, 2019)
- Confirmatory Offer Letter between the Registrant and Robert King, Ph.D (Filed With SEC on January 29, 2019)
- Confirmatory Offer Letter between the Registrant and Sabah Oney, Ph.D (Filed With SEC on January 29, 2019)
- Confirmatory Offer Letter between the Registrant and Calvin Yu (Filed With SEC on January 29, 2019)
- Form of Underwriting Agreement, including Form of Lock-up Agreement (Filed With SEC on January 7, 2019)
- Amended and Restated Registration Rights Agreement among the Registrant and certain of its stockholders, dated April 26, 2018 (Filed With SEC on January 7, 2019)
- Specimen common stock certificate of the Registrant (Filed With SEC on January 7, 2019)
- Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on January 7, 2019)
- 2017 Stock Option and Grant Plan, as amended, and forms of agreement thereunder (Filed With SEC on January 7, 2019)
- 2019 Equity Incentive Plan and forms of agreements thereunder, to be in effect upon the completion of this offering (Filed With SEC on January 7, 2019)
- 2019 Employee Stock Purchase Plan, to be in effect upon the completion of this offering (Filed With SEC on January 7, 2019)
- Executive Incentive Compensation Plan (Filed With SEC on January 7, 2019)
- Outside Director Compensation Policy (Filed With SEC on January 7, 2019)
- Form of Change in Control and Severance Agreement between the Registrant and certain of its executive officers (Filed With SEC on January 7, 2019)
- Third Amended and Restated Collaboration Agreement between the Registrant and Adimab, dated September 19, 2016, as amended (Filed With SEC on January 7, 2019)
- Sublease between the Registrant and CytomX Therapeutics, Inc., dated April 25, 2016 (Filed With SEC on January 7, 2019)
- Lease between the Registrant and HCP Oyster Point III, LLC, dated June 27, 2018 (Filed With SEC on January 7, 2019)
- Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology, Ltd., dated October 16, 2017 (Filed With SEC on January 7, 2019)
